CureVac NV
Industry Group: Pharmaceuticals
Country/Region: Germany
Identifier: NAS:CVAC
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 718 out of 851
Universe
Global Universe 13124 out of 15100
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| Tourmaline Bio, Inc. |
24
Medium
|
162 out of 851 |
| Stoke Therapeutics, Inc. |
25.2
Medium
|
199 out of 851 |
| Arbutus Biopharma Corp. |
25.5
Medium
|
216 out of 851 |
| Monte Rosa Therapeutics, Inc. |
29.3
Medium
|
412 out of 851 |
| CureVac NV |
36.4
High
|
718 out of 851 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted CureVac NV's ESG Risk Rating in the last three years
Highest Controversy Level
Contributing Events
Highest Controversy Events Locations
